A proteasome is a large molecular machine inside your cells that breaks down proteins your body no longer needs. Think of it as a cellular recycling center: it chews up damaged, misfolded, or outdated proteins into small fragments that the cell can reuse as raw building material. Nearly every cell in your body contains proteasomes, and they are essential for keeping the internal environment clean, regulating key processes like cell division, and enabling the immune system to identify threats.
How the Proteasome Is Built
The full working proteasome, called the 26S proteasome, has two main parts: a barrel-shaped core and a pair of regulatory caps. The core (the 20S particle) is where the actual protein-cutting happens. It is made of four stacked rings, each containing seven protein subunits. The two outer rings are built from seven different “alpha” subunits, and the two inner rings from seven different “beta” subunits. Of those beta subunits, three in each ring carry the active cutting sites. The whole assembly forms a hollow tube, and proteins must enter this tube to be destroyed.
Sitting on one or both ends of the barrel is a regulatory cap called the 19S particle. This cap is itself a complex of at least 18 different proteins, divided into a “base” and a “lid.” The base contains six subunits that use cellular energy (ATP) to unfold target proteins and thread them into the core. The lid recognizes the molecular tag that marks a protein for destruction. Together, the cap and the core ensure that only the right proteins get degraded.
The Ubiquitin Tagging System
Cells don’t randomly feed proteins into the proteasome. Instead, they use a precise labeling system built around a small protein called ubiquitin. When a protein needs to be removed, a chain of ubiquitin molecules is attached to it through a series of enzymatic steps. This polyubiquitin chain acts like a shipping label, flagging the protein for pickup. The 19S cap on the proteasome has a binding site that recognizes this chain, pulls the tagged protein in, and strips off the ubiquitin tags so they can be recycled and used again.
Once the tagged protein is captured, the energy-burning subunits in the base unfold it into a long strand and push it through a narrow opening (roughly one nanometer wide) into the hollow core. Inside, the cutting sites on the beta subunits slice the protein into short peptide fragments, typically seven to nine amino acids long. These fragments are then released back into the cell.
Three Ways It Cuts Proteins
The proteasome doesn’t cut proteins at random points. Each of its three active beta subunits has a different cutting preference. One has “chymotrypsin-like” activity, meaning it cuts after large, water-repelling amino acids. Another has “trypsin-like” activity, cutting after positively charged amino acids. The third has “caspase-like” activity, cutting after acidic amino acids. Because the core contains two copies of each active subunit (one in each inner ring), a single proteasome has six cutting sites in total. This combination lets it efficiently reduce almost any protein to small pieces.
Where Proteasomes Work Inside Cells
Proteasomes are found in both the cytoplasm and the nucleus. They are initially assembled in the cytoplasm, then many of them move into the nucleus, where they help regulate gene activity by degrading proteins that sit on DNA and control which genes are turned on or off. This movement is not random. Research shows that proteasomes bind to chromosomes in a pattern that changes with the cell cycle. In resting cells, nuclear proteasomes tend to sit on chromatin (the tightly packed form of DNA), but they release from it when the cell re-enters active division.
In yeast, proteasomes are even stored in specialized membrane-free compartments near the nucleus during periods of inactivity, then rapidly released and transported back into the nucleus within minutes when the cell needs to start growing again. This kind of dynamic repositioning highlights how tightly cells control where and when protein breakdown occurs.
What the Proteasome Does for Your Body
Protein recycling sounds like housekeeping, but it controls some of the most important decisions a cell makes. One key example is the protein p53, often called the “guardian of the genome.” Under normal conditions, p53 is continuously made and then quickly destroyed by the proteasome, keeping its levels low. When DNA damage occurs, this degradation slows down, p53 accumulates in the nucleus, and it activates genes that either halt cell division to allow repairs or trigger programmed cell death if the damage is too severe. By controlling how fast p53 is destroyed, the proteasome effectively acts as a switch between normal growth and emergency response.
The same logic applies to cyclins, the proteins that drive cells through each stage of division. As a cell progresses from one phase to the next, specific cyclins must be destroyed at exactly the right moment. The proteasome handles this timed destruction. If it fails, cells can divide uncontrollably, which is one hallmark of cancer.
The Immunoproteasome
Your immune cells use a specialized version called the immunoproteasome. It looks structurally similar to the standard proteasome, but three of its catalytic subunits are swapped out for alternative versions. These replacement subunits shift the cutting preferences, favoring fragments that end with water-repelling or positively charged amino acids. That matters because these particular fragment types fit neatly into the grooves of MHC class I molecules, the display platforms on cell surfaces that present protein fragments to immune cells.
The immunoproteasome is always active in T cells, B cells, and antigen-presenting cells. In other cell types, it can be switched on by inflammatory signals like interferon-gamma or tumor necrosis factor alpha. When your body fights an infection, ramping up immunoproteasome production helps cells display more viral or bacterial protein fragments on their surfaces, making it easier for the immune system to spot and kill infected cells.
When the Proteasome Fails
If proteasomes can’t keep up with the load of damaged proteins, those proteins accumulate and clump together into aggregates. This is a central feature of several neurodegenerative diseases. In Alzheimer’s disease, cells struggle to clear misfolded amyloid and tau proteins. In Parkinson’s disease, a protein called alpha-synuclein builds up in toxic clumps inside nerve cells. In both cases, proteasome dysfunction has been implicated in the disease process: the cellular inability to clear these abnormal proteins leads to deposits that damage and eventually kill neurons.
It is not always clear whether proteasome failure causes the aggregation or whether aggregation overwhelms and clogs the proteasome. Evidence suggests both directions can occur, creating a vicious cycle where initial protein buildup impairs proteasome function, which accelerates further buildup.
Proteasome Inhibitors as Cancer Treatment
Cancer cells divide rapidly, which means they produce enormous quantities of proteins and depend heavily on the proteasome to manage the load. This dependency makes the proteasome a drug target. In 2003, the FDA approved bortezomib (sold as Velcade) as the first proteasome inhibitor for treating multiple myeloma, a blood cancer. It was later also approved for mantle cell lymphoma after a trial of 155 patients showed a 32% overall response rate.
Bortezomib works by reversibly blocking the main cutting site in the proteasome. With protein breakdown stalled, regulatory proteins like p53 accumulate inside cancer cells, triggering growth arrest and cell death. A second-generation inhibitor, carfilzomib (Kyprolis), was approved in 2012. Unlike bortezomib, carfilzomib binds irreversibly to its target and can produce responses in some patients whose cancer has stopped responding to bortezomib. Both drugs are now standard tools in treating multiple myeloma at various stages of the disease.
The success of proteasome inhibitors confirmed something that researchers had long suspected: the proteasome is not just a passive garbage disposal. It is an active regulatory hub, and disrupting it can tip cancer cells over the edge into self-destruction while sparing most normal cells, which are less dependent on maximal proteasome output.